Technology News and Research

RSS

Innovative MD leadership program for medical students

The first medical students enrolled in SELECT, an innovative program designed to educate the physician leaders of the future, will arrive on the USF Health campus this week.

27 Jul 2011

Special panel votes in favor of HDE approval for EXCOR Pediatric VAD

At the request of Dr. Bram Zuckerman, Director, Division of Cardiovascular Devices, Center for Devices and Radiologic Health of the United States Food and Drug Administration, a special panel was convened on Thursday July 21 in Gaithersburg, Maryland to review the results of the EXCOR® IDE clinical trial.

27 Jul 2011

Roundup: Md. to release cancer control plan; funding cut at Texas mental health centers

Maryland health officials plan to release today their newest plan to control cancer, a set of diseases responsible for one in four deaths in the state. The officials say the plan to be used by health care providers, policy makers, communities and individuals is ambitious, aiming to save some 1,200 more people a year. Now, about 10,000 Marylander die a year from all kinds of cancer.

27 Jul 2011

Ceridia completes CER006 Phase 1 Proof-of-Concept study in humans

Ceridia Pty Ltd., a biotechnology company focused on reformulating and developing therapeutic drugs, announce the successful completion of Phase 1 Proof-of-Concept study of its novel LipoCeramic ibuprofen formulation, CER006.

27 Jul 2011

NSU, Immunotec collaborate to determine effects of Immunocal on children with ASD

Immunotec Inc. announces that Nova Southeastern University (NSU) in Florida is conducting a study to determine the effects of Immunocal on the behaviours of children with autism spectrum disorder.

27 Jul 2011

FDA clears ArthroCare's SpeedFix Suture System

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its SpeedFix Suture System.

27 Jul 2011

Selexis, CSL enter commercial license agreement for therapeutic antibody

Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.

26 Jul 2011

Kadmon, Dyax enter license agreement for antibody phage display libraries

Dyax Corp. and Kadmon Corporation, LLC announced today that Dyax has granted Kadmon a non-exclusive license to Dyax's proprietary "gold-standard" antibody phage display libraries for the discovery and development of therapeutic antibodies.

26 Jul 2011

Kinetic Concepts second quarter total revenue increases 4% to $519.8 million

Kinetic Concepts, Inc. today reported second quarter 2011 total revenue of $519.8 million, an increase of 4% from the second quarter of 2010.

26 Jul 2011

BioWa, arGEN-X sign license agreement for POTELLIGENT Technology

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT Technology.

26 Jul 2011

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Biogen Idec and Swedish Orphan Biovitrum today announced Phase 1/2a trial data showing that the companies' long-lasting fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) was well tolerated and demonstrated an approximately 1.7-fold increase in half-life compared with Advate, a commercially-available factor VIII product, in 16 previously-treated patients with severe hemophilia A.

26 Jul 2011

East Africa famine highlights need for better science communications

The drought in the Horn of Africa "emphasizes the gap between our rapidly increasing ability to predict disasters, thanks largely to advances in science and technology, and our capacity to generate the political will to carry out effective mitigation strategies," according to a SciDev.Net opinion piece by editor David Dickson.

26 Jul 2011

CANARY software can protect nation's water systems from contamination

Americans are used to drinking from the kitchen tap without fear of harm, even though water utilities might be vulnerable to terrorist attacks or natural contaminants.

26 Jul 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

New larger lumen catheter for clot removal in ischemic stroke patients

Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients and distal access solutions, today announced the launch of the DAC 070 Catheter.

26 Jul 2011

Foot care tips for diabetes patients

With the peak of summer now upon us, many of us will take time to kick off the shoes and take a walk on the beach or maybe on a grassy field in the local park. Some may even hop into a river or creek to cool off. No worries, right? Well, for some people, relaxing barefoot comes with some concern. Specifically, those with diabetes need to pay close attention to their feet.

26 Jul 2011

Artificial lung reaches efficiencies akin to the genuine organ

An artificial lung built by Cleveland researchers has reached efficiencies akin to the genuine organ, using air - not pure oxygen as current man-made lungs require - for the source of the essential element.

26 Jul 2011

GCMS, PBS Biotech sign distribution agreement for single-use bioreactors in Korea

PBS Biotech, Inc., a developer of state of the art single-use bioreactors for the fast growing biotechnology market, announced today it has signed an exclusive distribution agreement in Korea with Green Cross Medical Sciences Corp. (GCMS), a division of Green Cross Corporation, one of Korea's largest pharmaceutical firms.

26 Jul 2011

UC San Diego receives NHLBI 'Program of Excellence in Glycosciences' grant

Scientists at the University of California, San Diego School of Medicine have received a major 7-year, $18 million grant to begin translating emerging discoveries in the field of glycosciences into new discoveries and therapies related to heart, lung and blood diseases.

26 Jul 2011

Researchers identify elusive gene responsible for Grey Platelet Syndrome

Researchers have identified an elusive gene responsible for Grey Platelet Syndrome, an extremely rare blood disorder in which only about 50 known cases have been reported. As a result, it is hoped that future cases will be easier to diagnose with a DNA test.

26 Jul 2011